Aspirin Toxicity: ED Management in 5 Minutes

This comprehensive section covers the complete pharmacology of salicylates and aspirin. COX enzymes are classified into three types: COX-1 (kidneys and stomach), COX-2 (site-specific inflammation), and COX-3 (CNS effects including fever and pain). Salicylates are derived from salicylic acid, which cannot be used systemically due to severe irritation. Modifications like acetylation (producing aspirin) and sodium addition enable systemic use. Pharmacokinetics include absorption from stomach and small intestine, widespread distribution crossing blood-brain and placental barriers, 50-80% protein binding to albumin, hepatic metabolism via glucuronidation, and renal excretion. Half-life is short (15 min for aspirin, 1.5 hours for salicylic acid), with first-order kinetics at therapeutic doses and zero-order kinetics at toxic doses. Mechanism of action involves irreversible COX inhibition through acetylation, preventing prostaglandin synthesis. Effects on CNS include analgesia (reducing prostaglandins in thalamus and periphery) and antipyresis (acting on hypothalamic thermoregulatory center). Anti-inflammatory action results from COX-2 inhibition at inflammation sites, reducing prostaglandins, thromboxane A2, histamine, bradykinin, and leukotrienes. At toxic doses, aspirin uncouples oxidative phosphorylation, causing hyperthermia. Organ system effects include respiratory (bronchospasm in aspirin-sensitive individuals), GI (gastric irritation, peptic ulcers), and renal (reduced prostaglandins causing vasoconstriction). Clinical applications include analgesia, antipyresis, anti-inflammatory effects (rheumatoid arthritis, rheumatic fever, gout), and antiplatelet therapy. Contraindications include G6PD deficiency (hemolysis), Reye's syndrome in children with viral infections, peptic ulcers, asthma, and pregnancy.

Salicylates are a group of drugs derived from salicylic acid, with aspirin (acetylsalicylic acid) being the most prominent member. The group is classified based on their mechanism of action on cyclooxygenase (COX) enzymes. Unlike NSAIDs, salicylates have a weaker effect on COX inhibition, resulting in reduced risk of complications such as bleeding and gastrointestinal issues. Aspirin was first synthesized in 1899 by Felix Hoffmann at Bayer, and the name 'aspirin' is derived from the German chemical structure 'acetylsalicylic acid'. Aspirin undergoes hydrolysis in the plasma, where the acetyl group is removed to form salicylic acid, which is the active metabolite responsible for most of aspirin's pharmacological effects. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid aspirin because it can cause hemolysis. Aspirin metabolism follows first-order kinetics at low doses (less than 5 grams per day), where the elimination rate is proportional to drug concentration. However, at high doses (5 grams or more per day), aspirin metabolism switches to zero-order kinetics, where the elimination rate becomes constant regardless of concentration. This dose-dependent change in kinetics can lead to drug accumulation and increased risk of toxicity at high doses. Aspirin has different therapeutic effects at different doses: low doses (75-150 mg daily) are used for antiplatelet effects and cardiovascular protection, medium doses (1-2 grams daily) are used for analgesic and antipyretic effects, and high doses (5 grams or more daily) are used for anti-inflammatory effects in conditions like rheumatoid arthritis. Aspirin's antiplatelet effect is due to its irreversible inhibition of cyclooxygenase-1 (COX-1) in platelets, preventing thromboxane A2 formation and reducing platelet aggregation. Aspirin's analgesic effect is due to its inhibition of prostaglandin production in pain-sensitive tissues, reducing the sensitivity of pain receptors. Aspirin reduces fever by acting on the hypothalamus to reset the body's temperature set point, inhibiting prostaglandin production that normally maintains the elevated set point. Aspirin's anti-inflammatory effect is due to its inhibition of prostaglandin production in inflamed tissues, reducing vasodilation, increased vascular permeability, and sensitization of pain receptors. The anti-inflammatory effect requires higher doses of aspirin compared to its analgesic and antipyretic effects.

At low doses, aspirin follows first-order elimination where a constant percentage is eliminated per unit time, with a half-life of approximately 3.5 hours. At high anti-inflammatory doses (>4g/day), hepatic metabolic pathways become saturated, switching to zero-order elimination where a constant amount is eliminated per unit time. This causes the half-life to increase to 15 hours or more, requiring 5-6 half-lives to eliminate half of the drug.

Analgesics are classified based on their mechanism of action and potency. Non-opioid analgesics (like aspirin, acetaminophen, NSAIDs) work by inhibiting prostaglandin production and are used for mild to moderate pain. Opioid analgesics (like morphine, codeine) work by binding to opioid receptors in the central nervous system and are used for severe pain. Aspirin dosing varies based on clinical indication: low-dose (81mg) for cardiovascular protection, therapeutic doses (325-650mg) for pain and inflammation, and high doses for anti-inflammatory effects. Salicylates are metabolized in the liver and eliminated primarily through the kidneys as salicylic acid. At therapeutic doses, elimination follows first-order kinetics (constant percentage eliminated per unit time). At high doses, elimination switches to zero-order kinetics (constant amount eliminated per unit time). Salicylates are weak acids that can be absorbed through the skin, making topical preparations possible.

Salicylates, particularly aspirin, work by inhibiting cyclooxygenase (COX) enzymes, which reduces prostaglandin production and platelet aggregation. They are distributed in the body with 80-90% protein binding and primarily metabolized in the liver. Toxicity presents with three key features: hyperthermia, hyperventilation, and metabolic acidosis. Acute toxicity can cause Reye's syndrome in children under 4 years, while chronic toxicity leads to metabolic acidosis. Treatment involves alkalinization of urine and hemodialysis for severe cases.

This section explains ion trapping—the phenomenon where charged drug forms accumulate in specific body compartments because only uncharged molecules can cross lipid membranes. For weak acids: acidic environments favor uncharged HA (absorption), while alkaline environments trap charged A-. For weak bases: opposite behavior. Clinical applications include: aspirin absorption from stomach (pH 1.5 favors HA), blood distribution (pH 7.4 traps A-), and renal elimination. Urinary alkalinization with bicarbonate increases aspirin excretion by trapping it in urine, serving as a primary treatment for aspirin overdose.

Drug absorption depends on ionization state relative to pH. Weak acids are best absorbed in the stomach (pH 1.5-1.8) where pH is lower than pKa (3.5), keeping them nonionized and lipid-soluble for easy membrane crossing. In blood (pH 7.4), the higher pH causes the drug to lose its proton and become ionized. This ionization traps the drug in the blood, preventing diffusion back into the stomach. This phenomenon is called ion trapping. Nonionized drugs cross membranes easily, while ionized drugs become trapped. Aspirin is a classic example. The mechanism applies to various clinical scenarios including drug overdose treatment and fetal circulation where weak bases cross the placenta and become ionized in lower fetal pH, getting trapped in fetal circulation.

Ion trapping is a pharmacological phenomenon where substances accumulate in body compartments due to pH differences. Biological membranes are phospholipid bilayers with selective permeability controlled by three determinants: electrical charge (charged substances cross with difficulty), liposolubility (higher liposolubility = easier crossing), and molecular weight (lower weight = easier crossing). Living organisms maintain pH gradients between compartments (e.g., stomach pH 1-5 vs plasma pH 7.4). For acids, when pH < pKa, the non-ionized form predominates and diffuses easily; when pH > pKa, the ionized form predominates and cannot cross membranes. This creates concentration differences between compartments, with substances becoming trapped in compartments where they ionize.

Weak base drugs exist in equilibrium between ionized (BH+) and unionized (B) forms. Only the unionized form can cross biological membranes via simple diffusion. The Henderson-Hasselbalch equation (pH = pKa + log[B/BH+]) predicts ionization state based on pH relative to pKa. When pH > pKa, basic conditions favor dissociation to produce more unionized drug; when pH < pKa, acidic conditions favor protonation to produce more ionized drug. This principle explains why drug distribution between body compartments depends on pH differences.

Drugs cross biological membranes through passive diffusion (down gradient, lipid-soluble), facilitated diffusion (carrier-mediated, still down gradient), and active transport (against gradient, requires energy). Most drugs are weak electrolytes existing in equilibrium between ionized and non-ionized forms. The Henderson-Hasselbalch equation (log([HA]/[A⁻]) = pKa - pH) predicts ionization at any pH. When pH = pKa, half the drug is ionized. Ion trapping occurs when drugs accumulate on one membrane side due to pH differences—weak acids trap in basic compartments, weak bases trap in acidic compartments. This principle explains why weak acids like aspirin cross gastric membranes (acidic pH) but accumulate in plasma (basic pH).

Uncouplers are substances that disrupt the normal coupling between electron transport and ATP synthesis in mitochondria by short-circuiting the proton gradient, allowing electrons to flow freely but preventing ATP production; instead, the energy is released as heat, causing hyperthermia, and examples include thermogenin (found in brown fat tissue of newborns), dinitrophenol, aspirin, and alcohol, which differ from electron transport chain inhibitors like carbon monoxide and cyanide that directly block ATP synthesis.

Uncouplers are substances that disrupt the coupling between electron transport and ATP synthesis in oxidative phosphorylation. They work by creating channels in the inner mitochondrial membrane that allow hydrogen ions to flow back into the matrix without passing through ATP synthase. This dissipates the proton gradient that drives ATP production. As a result, oxygen consumption increases (because the electron transport chain continues to function) but ATP production decreases. Some natural uncouplers, like those found in chili peppers, cause the sensation of heat because the energy that would have been used to produce ATP is instead released as heat.

Scientists discovered substances (uncoupling agents) that allow oxygen consumption to continue without ATP synthesis. These agents disrupt the coupling between oxidation and phosphorylation, revealing that the two processes are normally linked but can be separated. Uncoupling agents like 2,4-dinitrophenol can cause severe illness and death by disrupting cellular energy metabolism, causing intense weight loss, blindness, and other symptoms. This toxicity demonstrates the critical importance of proper coupling between oxidation and phosphorylation for survival.

Under normal conditions, the body intentionally reduces mitochondrial energy conversion efficiency through uncoupling, allowing protons to bypass ATP synthase and interact with enzymes in incorrect sequences. This process generates heat through cellular warming. When alcohol causes total uncoupling across all mitochondria simultaneously, it could theoretically cause human spontaneous combustion, though this phenomenon remains unacknowledged by mainstream science despite documented evidence.

Inhibitors of oxidative phosphorylation disrupt the proton gradient: oligomycin blocks ATP synthase, valinomycin creates artificial gradients, nigericin exchanges protons for cations, and atractyloside inhibits ADP/ATP translocase. Uncouplers break the link between electron transport and ATP synthesis by increasing inner mitochondrial membrane permeability to protons. This prevents gradient formation, releasing energy as heat instead of ATP. Examples include 2,4-dinitrophenol, DNP, and pentachlorophenol.